Easier and more accessible testing for SARS-CoV-2 (COVID-19)
Ubiquitome has partnered with The SalivaDirect Initiative at Yale School of Public Health to enhance public access to COVID-19 testing, with United States Food and Drug Administration (FDA) emergency use authorization (EUA) of the combination of SalivaDirect™ with Ubiquitome’s Liberty16 mobile real time-PCR.
In Yale School of Public Health testing the Liberty16 displayed performance similar to large, lab-bound instruments.
|Proteinase K||Primer/Probe||RT-qPCR kit||RT-qPCR instrument||LOD||Positive replicates||Mean Ct value (SD)|
|Thermo||IDT||NEB Luna (2x)||Agilent AriaMX||6 copies/μL||100% (20/20)||30.3 (0.4)|
|Thermo||Eurofins||NEB Luna (2x)||Liberty16||12 copies/μL||100% (20/20)||35.18 (0.7)|
|Thermo||IDT||NEB Luna (2x)||CFX384 Touch||6 copies/μL||100% (20/20)||36.25 (0.4)|
Liberty16 Workplace Surveillance Testing for COVID-19
Now available for small and medium sized workplaces, with affordable on-site gold standard PCR testing to keep costs down, productivity up and your staff COVID safe.
NIH RADx winner’s next gen Liberty16 Pro gets EUA Auckland, December 19, 2022: Ubiquitome’s next generation real time PC...
Faster mobile PCR test device helping business continuity Chicago, July 27, 2022: Ubiquitome , which won through the Uni...
"Costly instruments for real-time PCR analysis often stand in the way of equitable access for under resourced communities and countries and sustainability of testing systems"
Dr Anne Wyllie, Yale School of Public Health (on why they partnered with Ubiquitome)